NO20073760L - Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister - Google Patents
Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonisterInfo
- Publication number
- NO20073760L NO20073760L NO20073760A NO20073760A NO20073760L NO 20073760 L NO20073760 L NO 20073760L NO 20073760 A NO20073760 A NO 20073760A NO 20073760 A NO20073760 A NO 20073760A NO 20073760 L NO20073760 L NO 20073760L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- tetrazolone
- triazolone
- alzheimer
- disease
- Prior art date
Links
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title abstract 2
- OUOJIFQQBPKAMU-UHFFFAOYSA-N tetrazol-5-one Chemical compound O=C1N=NN=N1 OUOJIFQQBPKAMU-UHFFFAOYSA-N 0.000 title abstract 2
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical compound O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 title abstract 2
- 108050002082 Alpha 2C adrenoceptor Proteins 0.000 title 1
- 102100025983 Alpha-2C adrenergic receptor Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000674 adrenergic antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse vedrører substituerte triazolon-, tetrazolon- og imidazolonderivater i henhold til den generelle formel (I) (I) et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav, en stereokjemisk isomer form derav, en N-oksidform derav eller et kvaternært ammoniumsalt derav, hvori variablene er definert i krav 1, som har selektiv ?2C-adrenoreseptorantagonistaktivitet. Den vedrører ytterligere deres fremstilling, sammensetninger omfattende dem og deres anvendelse som en medisin. Forbindelsene ifølge oppfinnelsen er nyttige for forebyggingen og/eller behandlingen av sentralnervesystemlidelser, sinnsstemningslidelser, angstlidelser, stressrelaterte lidelser assosiert med depresjon og/eller angst, kognitive lidelser, personlighetslidelser, schizoaffektive lidelser, Parkinsons sykdom, demens av Alzheimer-typen, kroniske smertetilstander, nevrodegenerative sykdommer, avhengighetslidelser, sinnsstemningslidelser og seksuell dysfunksjon. ?? ?? ?? ?? 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04106817 | 2004-12-21 | ||
| EP05104873 | 2005-06-03 | ||
| PCT/EP2005/056951 WO2006067139A1 (en) | 2004-12-21 | 2005-12-20 | Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073760L true NO20073760L (no) | 2007-07-19 |
Family
ID=36013649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073760A NO20073760L (no) | 2004-12-21 | 2007-07-19 | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100029620A1 (no) |
| EP (1) | EP1831185A1 (no) |
| JP (1) | JP2008524312A (no) |
| KR (1) | KR20070090941A (no) |
| AR (1) | AR052342A1 (no) |
| AU (1) | AU2005318188A1 (no) |
| BR (1) | BRPI0516380A (no) |
| CA (1) | CA2588028A1 (no) |
| EA (1) | EA011514B1 (no) |
| IL (1) | IL184048A0 (no) |
| MX (1) | MX2007007472A (no) |
| NO (1) | NO20073760L (no) |
| PA (1) | PA8657301A1 (no) |
| TW (1) | TW200635906A (no) |
| WO (1) | WO2006067139A1 (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| AU2011308403B2 (en) * | 2010-10-01 | 2014-08-21 | Taisho Pharmaceutical Co., Ltd. | 1,2,4-triazolone derivative |
| FR2976287B1 (fr) | 2011-06-09 | 2013-07-05 | Pf Medicament | Derives benzoquinolizidines, leur procede de preparation et leurs applications en therapeutique |
| KR101998442B1 (ko) * | 2011-10-27 | 2019-07-09 | 다이쇼 세이야꾸 가부시끼가이샤 | 아졸 유도체 |
| CN104334547B (zh) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| KR20160018543A (ko) * | 2013-06-11 | 2016-02-17 | 에프. 호프만-라 로슈 아게 | 신규한 테트라졸론 유도체 |
| EP3013342B1 (en) | 2013-06-27 | 2021-04-14 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| US20190297887A1 (en) | 2016-07-12 | 2019-10-03 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
| CA3079819C (en) * | 2017-11-06 | 2023-03-14 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation |
| JP2021183586A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3355457A (en) * | 1965-05-21 | 1967-11-28 | American Cyanamid Co | Substituted 2-imidazolinones |
| DE2725148A1 (de) * | 1977-06-03 | 1978-12-14 | Hoechst Ag | 1-aryl-4-alkyl-1,2,4-triazol-5-one und verfahren zu ihrer herstellung |
| PT741737E (pt) * | 1994-01-24 | 2000-04-28 | Janssen Pharmaceutica Nv | Antifungicos do tipo azole soluveis em agua |
| JPH0899975A (ja) * | 1994-08-05 | 1996-04-16 | Nippon Bayeragrochem Kk | ５員複素環置換テトラゾリノン誘導体および除草剤 |
| JPH09183770A (ja) * | 1995-10-31 | 1997-07-15 | Nippon Bayeragrochem Kk | １−アジン−テトラゾリノン類及び除草剤 |
| WO1998025912A1 (en) * | 1996-12-13 | 1998-06-18 | E.I. Du Pont De Nemours And Company | Herbicidal heterocyclic amides |
| AU7365698A (en) * | 1997-05-15 | 1998-12-08 | E.I. Du Pont De Nemours And Company | Herbicidal tetrazolinones |
| EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| JP3837242B2 (ja) * | 1998-08-25 | 2006-10-25 | 北興化学工業株式会社 | トリアゾリノン誘導体および除草剤 |
| WO2000010984A1 (en) * | 1998-08-19 | 2000-03-02 | Hokko Chemical Industry Co., Ltd. | Triazolinone derivatives and herbicide compositions |
-
2005
- 2005-12-19 AR ARP050105336A patent/AR052342A1/es not_active Application Discontinuation
- 2005-12-20 US US11/722,380 patent/US20100029620A1/en not_active Abandoned
- 2005-12-20 EA EA200701345A patent/EA011514B1/ru not_active IP Right Cessation
- 2005-12-20 MX MX2007007472A patent/MX2007007472A/es unknown
- 2005-12-20 AU AU2005318188A patent/AU2005318188A1/en not_active Abandoned
- 2005-12-20 CA CA002588028A patent/CA2588028A1/en not_active Abandoned
- 2005-12-20 PA PA20058657301A patent/PA8657301A1/es unknown
- 2005-12-20 WO PCT/EP2005/056951 patent/WO2006067139A1/en not_active Ceased
- 2005-12-20 JP JP2007547485A patent/JP2008524312A/ja active Pending
- 2005-12-20 BR BRPI0516380-3A patent/BRPI0516380A/pt not_active IP Right Cessation
- 2005-12-20 KR KR1020077014061A patent/KR20070090941A/ko not_active Withdrawn
- 2005-12-20 EP EP05823472A patent/EP1831185A1/en not_active Withdrawn
- 2005-12-21 TW TW094145703A patent/TW200635906A/zh unknown
-
2007
- 2007-06-19 IL IL184048A patent/IL184048A0/en unknown
- 2007-07-19 NO NO20073760A patent/NO20073760L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR052342A1 (es) | 2007-03-14 |
| PA8657301A1 (es) | 2007-01-17 |
| AU2005318188A1 (en) | 2006-06-29 |
| EA011514B1 (ru) | 2009-04-28 |
| CA2588028A1 (en) | 2006-06-29 |
| EP1831185A1 (en) | 2007-09-12 |
| MX2007007472A (es) | 2007-07-20 |
| BRPI0516380A (pt) | 2008-09-02 |
| TW200635906A (en) | 2006-10-16 |
| JP2008524312A (ja) | 2008-07-10 |
| EA200701345A1 (ru) | 2007-10-26 |
| KR20070090941A (ko) | 2007-09-06 |
| WO2006067139A1 (en) | 2006-06-29 |
| IL184048A0 (en) | 2007-10-31 |
| US20100029620A1 (en) | 2010-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister | |
| NO20073719L (no) | Kjemiske forbindelser | |
| WO2010039186A3 (en) | Benzoxazoles useful as faah modulators and uses thereof | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| ATE454372T1 (de) | Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen | |
| IL198072A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| ECSP056192A (es) | 3-fluoro-piperidinas como antagonistas de nmda/nr2b | |
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
| WO2009121155A3 (en) | Flavone containing compositions for treating mao associated disorders | |
| NO20072972L (no) | Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler | |
| WO2008077810A3 (en) | Spiro-piperidine derivatives | |
| NO20084819L (no) | Substituerte pyrazinonderivater for anvendelse som en medisin | |
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| NO20091830L (no) | Spiro-piperidinderivater som VIa reseptorantagonister | |
| NO20052172D0 (no) | 4-aminopiperidinderivater, fremgangsmate for deres fremstilling og deres anvendelse som medikamenter | |
| NO20055758L (no) | Heteroarylsubstituerte imidazolderivater som glutamatreseptorantagonister | |
| MX2010009820A (es) | 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a. | |
| ATE440826T1 (de) | Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen | |
| ATE505193T1 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
| BRPI0406884A (pt) | Derivados de diazepans úteis como inibidores de lfa | |
| BRPI0512404A (pt) | inibidores de mao-b | |
| ATE420635T1 (de) | Verwendung von 1-oxadibenzo äe,hü azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |